In the last few years, MFN2 in the pathogenesis of AD has become a research hot spot (Kim et al., 2017; Leal et al., 2020; Sita et al., 2020; Wang et al., 2021), and the present study provides a strong support for the hypothesis that MFN2 may serve as a therapeutic target for AD. This evidence concerns the gene MFN2 and Alzheimer disease.